Abstract: A mechanical rotational drive has a bar-like torsion element, whereby the torsion element is firmly clamped with a first end in a bearing device. The torsion element can be pivoted with a second free end with respect to the clamped end about the longitudinal axis, forming a rotation axis, of the torsion element between a relaxed position and a tensioned position, whereby the length of the torsion element is reduced with respect to the relaxed position when the torsion element is brought into its tensioned position.

Abstract: A mechanical rotational drive has a bar-like torsion element, whereby the torsion element is firmly clamped with a first end in a bearing device. The torsion element can be pivoted with a second free end with respect to the clamped end about the longitudinal axis, forming a rotation axis, of the torsion element between a relaxed position and a tensioned position, whereby the length of the torsion element is reduced with respect to the relaxed position when the torsion element is brought into its tensioned position.

Abstract: A support structure includes at least one shaped component which is produced from a shape memory alloy and which, in a first operating state of the support structure, results in an increase in the strength of the support structure and, in a second operating state, results in a reduction in the thermal conductivity of the support structure. The first strut structure is surrounded by a second strut structure, which has a higher mechanical strength in comparison with the first strut structure, and the first strut structure is connected securely, at least at one of its ends, to the second strut structure. In addition, the first strut structure is connected to a holding device, and the second strut structure is releasably connected to the holding device by the at least one shaped component.

Abstract: A mechanical support structure has at least one molded component made of a shape memory alloy, which in a first operating mode of the support structure yields an increase in the stability of the support structure and in a second operating mode yields a reduction in the thermal conductivity of the support structure. A strut structure is enclosed by a tubular structure which possesses a higher level of mechanical stability than the strut structure. The strut structure s permanently fastened to the tubular structure at a first end. The strut structure is connected to a mounting element. The tubular structure is separably connected to the mounting element and the strut structure at a second end of the strut structure via the at least one molded component.

Abstract: The present invention relates to terpene ethers of the general formula (I) in which the substituents have the meanings defined in the description, to a process for their preparation and to their use. The novel terpene ethers are suitable as traction fluids, as fragrances, as solvents and as reactive intermediates.

Abstract: A support structure includes at least one shaped component which is produced from a shape memory alloy and which, in a first operating state of the support structure, results in an increase in the strength of the support structure and, in a second operating state, results in a reduction in the thermal conductivity of the support structure. The first strut structure is surrounded by a second strut structure, which has a higher mechanical strength in comparison with the first strut structure, and the first strut structure is connected securely, at least at one of its ends, to the second strut structure. In addition, the first strut structure is connected to a holding device, and the second strut structure is releasably connected to the holding device by the at least one shaped component.

Abstract: Benzyloxy-substituted, fused N-heterocycles, because of their ability to act as bradykinin receptor antagonists, have been found to be useful as therapeutics for the treatment and prevention of liver cirrhosis or Alzheimer's disease. This application describes such compounds, as well as processes for their preparation and use. The compounds according to this invention include compounds of formula (I) in which B, D, R1, and R2 have the meanings indicated herein.

Abstract: A process for preventing overturning during the landing of an aircraft or spacecraft using an air bag type landing impact-damping system, which is inflated with gas before the landing and from which gas is discharged via discharge valves during the landing. The process includes using as the air bag type landing impact-damping system a system that is divided into a plurality of chambers that can be inflated with gas and from which gas is released independently from one another, and that a pressure difference is generated during landing in the individual chambers of the air bag type landing impact-damping system.

Abstract: Aminoalkyl and acylaminoalkyl ethers which are distinguished by high affinity for the bradykinin B.sub.2 receptor and improved solubility in water are described. These aminoalkyl and acylaminoalkyl ethers can be represented by the formula (I) ##STR1## in which R.sup.1,R.sup.2,R.sup.3 are alkyl, aryl, alkylaryl, halogen, hydrogen, cycloalkyl, CHO, CO--O-alkyl, COOH; R.sup.4, R.sup.5 are hydrogen, halogen, alkoxy, nitro, cyano, S-alkyl; n is a number from 1 to 8; R.sup.6 is hydrogen, alkyl, alkylalkenyl, alkylaryl; R.sup.7 is hydrogen and a substituted or unsubstituted acyl radical. A process for preparing the compounds of the formula (I) is likewise described.

Abstract: The detonating valve for releasing openings of air bag landing systems for aircraft and spacecraft has a wedge type charge and a cover closing the opening, which cover is shorn off during the ignition of the wedge type charge. The cover is a thin-walled disk or a membrane, which is integrated either within the aircraft and spacecraft or within the air bag landing system.

Abstract: Fluoroalkyl- and fluoroalkoxy-substituted heterocyclic bradykinin antagonists, process or their preparation, and their useHeterocyclic fluoroalkyl derivatives and fluoroalkoxy derivatives of the formula (I) having bradykinin-antagonistic action ##STR1## in which X.sub.1 -X.sub.3 are N or CR.sup.5, R.sup.1 and R.sup.2 are H or halogen, R.sup.3 and R.sup.4 are H, halogen, alkyl or alkenyl, R.sup.5 is H, halogen, (substituted) alkyl, O--R.sup.6, S--R.sup.6, NHR.sup.6, (substituted) aryl, (substituted)aryl-alkyl, --C(O)--OR.sup.6 or --C(O)--H, R.sup.6 and R.sup.8 H, alkyl, alkenyl or aryl-alkyl, R.sup.7 is (substituted) alkyl or (substituted) alkoxy, B is an aminocarboxylic acid, D is alkenediyl, alkanediyl or --(CH.sub.2).sub.n --Y.sub.p --(CH.sub.2).sub.m --, E is oxygen or sulfur, Y is oxygen, sulfur or NR.sup.8, n and m are a number 0-3, o is a number 1-3 and p is 0 or 1, and their physiologically tolerable salts and a process for their preparation are described.

Abstract: Sulfur-containing heterocyclic bradykinin antagonists, process for their preparation, and their useCompounds of the formula (I) ##STR1## in which one of the radicals X.sub.1, X.sub.2 or X.sub.3 is C--O--R.sup.2 and the other X.sub.1, X.sub.2, and X.sub.3, in each case, and X.sub.4, are then, identically or differently, N or CR.sup.1 ; R.sup.1 and R.sup.3 are, identically or differently, H, halogen, (C.sub.1 -C.sub.6)-alkyl, O--R.sup.6, S--R.sup.6, NHR.sup.6, (C.sub.6 -C.sub.12)-aryl, (C.sub.6 -C.sub.12)-aryl-(C.sub.1 -C.sub.3)-alkyl, C(O)--OR.sup.6, C(O)--H, (C.sub.2 -C.sub.5)-alkenyl, NO.sub.2, SO.sub.3 R.sup.7, CN or C(O)--NHR.sup.8, where alkyl, aryl and alkenyl can optionally be substituted.

Abstract: The invention relates to the use of nonpeptide bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders (hepatic cirrhosis and hepatic fibrosis), acute liver disorders and for the prevention of complications, in particular for the prophylaxis or treatment of portal hypertension, decompensation symptoms such as ascites, edema formation, hepatorenal syndrome, hypertensive gastropathy and colopathy, splenomegaly and hemorrhagic complications in the gastrointestinal tract due to portal hypertension, collateral circulation and hyperemia and a cardiopathy as a result of a chronically hyperdynamic circulatory situation and its consequences.

Abstract: Aromatic bromomethyl compounds play a major role in the synthesis of active substances. They can be obtained in particularly pure form by the free-radical bromination of aromatic methyl compounds in the solvent chlorobenzene.

Abstract: A compound of the formula ##STR1## in which the symbols have the following meaning: X is a monocyclic radical having 3, 4 or 5 ring atoms,R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.12 and R.sup.13 are, for example, an alkyl radical,q is zero or 1,L is, for example, a methylene group andA is the radical, for example, of a heterocycleare highly active as antagonists of angiotensin II receptors.They can be used as pharmaceuticals or diagnostics.

Abstract: The invention relates to a process for the preparation of a compound of the formula (I) ##STR1## in which X is an optionally protected formyl group andR is a group which is itself inert to the reaction conditions of the synthesis,which comprises reacting a compound of the formula (II) ##STR2## where X is as defined above, with a substituted phenyl-halogen compound of the formula (III) ##STR3## where the substituent Hal is a halogen group and R is as defined above.

Abstract: Biphenyl derivatives and processes for the preparation of biphenyl derivatives are described. A compound of formula (I) is disclosed ##STR1## in which the substituent X is --CHO or --CH(OR.sup.1)OR.sup.2, where R.sup.1 and R.sup.2 independently of one another are (C.sub.1 -C.sub.6)-alkyl or R.sup.1 and R.sup.2 together are an alkylene group (--CH.sub.2).sub.n --, where n is 2, 3 4 or 5 and R is --F, --Cl, --NO.sub.2, --(CH.sub.2).sub.m --COOR.sup.3, --(CH.sub.2).sub.m --CONHR.sup.3, --(CH.sub.2).sub.m --CN, --SO.sub.2 NH--COOR.sup.3, --SO.sub.2 NH--CO--NHR.sup.3, --SO.sub.2 NH--SO.sub.2 --R.sup.3, --NHSO.sub.2 R.sup.3, ##STR2## --PO.sub.3 R.sup.3, --NH--SO.sub.2 --CF.sub.3, --SO.sub.2 NR.sup.4 where R.sup.3 is hydrogen, (C.sub.1 -C.sub.6)-alkyl, (C.sub.3 -C.sub.6)cycloalkyl, or (C.sub.1 -C.sub.6)-alkyl-(C.sub.3 -C.sub.6)cycloalkyl and R.sup.4 is a group .dbd.C--N(CH.sub.3).sub.2, and m is 0, 1, 2, 3, or 4.

Abstract: Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease.Antagonists for angiotensin II receptors of the AT.sub.1 subtype can be employed for the prophylaxis and combating of coronary heart disease.Furthermore these compounds, such as, for example, azoles of the formula (I) ##STR1## can also be used for the therapy of cognitive and erectile dysfunction.

Abstract: Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their useCompounds of the formula (I) ##STR1## in which R.sup.1 is, for example, ethyl,R.sup.2 is, for example, methyl,n is, for example, zero,R.sup.3 is, for example, COOH, andR.sup.4 is, for example, SO.sub.2 NHCONHCH.sub.3are highly active antagonists of angiotensin II receptors.

Abstract: A novel process for the preparation of a compound of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined in the text.